Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes

(2015)   Oncotarget

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

(2012) L G Feun et al.   BRITISH JOURNAL OF CANCER

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

(2010) T-S Yang et al.   BRITISH JOURNAL OF CANCER

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

(2010) Evan S. Glazer et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 /Sp4

(2009) W.-B. Tsai et al.   MOLECULAR CANCER THERAPEUTICS

Arginine Deprivation as a Targeted Therapy for Cancer

(2008) L. Feun et al.   CURRENT PHARMACEUTICAL DESIGN

Anti-cancer PEG-enzymes: 30 years old, but still a current approach

(2007) Gianfranco Pasut et al.   ADVANCED DRUG DELIVERY REVIEWS